Top

Gepubliceerd in:

06-09-2018

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

Auteurs: David F. McDermott, Ruchit Shah, Komal Gupte-Singh, Javier Sabater, Linlin Luo, Marc Botteman, Sumati Rao, Meredith M. Regan, Michael Atkins

Gepubliceerd in: Quality of Life Research | Uitgave 1/2019

Abstract

Purpose

To compare the quality-adjusted survival of nivolumab plus ipilimumab combination and nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma based on a minimum 36-month follow-up from the CheckMate 067 trial.

Methods

Overall survival was partitioned into time without symptoms of progression or toxicity (TWiST), time with treatment-related grade ≥ 3 adverse events after randomization but before progression (TOX), and time from progression until end of follow-up or death (REL). Mean quality-adjusted TWiST (Q-TWiST) was calculated by multiplying the mean time spent in each health state by a utility of 1.0 for TWiST and 0.5 for TOX and REL. Sensitivity analyses included varying utilities of TOX and REL; Q-TWiST gains at different follow-up times were calculated using EQ-5D-3L utilities from the trial. Relative Q-TWiST gain of ≥ 10% was considered clinically important.

Results

Compared with ipilimumab-treated patients, those who received nivolumab + ipilimumab combination had significantly longer TWiST and TOX but shorter REL; nivolumab-treated patients had significantly longer TWiST, shorter REL, and shorter but statistically nonsignificant TOX. Mean Q-TWiST was highest for nivolumab + ipilimumab (23.5 months; 95% CI 21.9–25.2), followed by nivolumab (21.8 months; 95% CI 20.2–23.4) and ipilimumab (15.3 months; 95% CI 13.9–16.6). Relative Q-TWiST gains were favorable and clinically important for nivolumab + ipilimumab combination (+ 36.81%) and nivolumab alone (+ 29.18%) versus ipilimumab alone. Relative gains increased with follow-up from 3 to 40 months for all comparisons. These gains remained consistent in magnitude and direction in the different sensitivity analyses.

Conclusions

Nivolumab + ipilimumab combination and nivolumab alone resulted in a statistically significant and clinically important improvement in quality-adjusted survival compared with ipilimumab alone.

vorige artikel Primary dysmenorrhea with and without premenstrual syndrome: variation in quality of life over menstrual phases

volgende artikel Health-related quality of life in people with advanced dementia: a comparison of EQ-5D-5L and QUALID instruments

Alleen toegankelijk voor geautoriseerde gebruikers

Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics. CA: A Cancer Journal for Clinicians, 67, 7–30.

American Cancer Society. (2018). Cancer facts & figs. 2018. Atlanta: American Cancer Society.

Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723. https://doi.org/10.1056/NEJMoa1003466.CrossRefPubMed

Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526. https://doi.org/10.1056/NEJMoa1104621.CrossRefPubMed

Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. American Journal of Clinical Oncology, 39(1), 98–106. https://doi.org/10.1097/COC.0000000000000239.CrossRefPubMedPubMedCentral

Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L., et al. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 390(10105), 1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X.CrossRefPubMed

Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., et al. (2016). Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: Results from the phase III CheckMate 066 study. Annals of Oncology, 27(10), 1940–1946. https://doi.org/10.1093/annonc/mdw265.CrossRefPubMedPubMedCentral

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372(4), 320–330. https://doi.org/10.1056/NEJMoa1412082.CrossRefPubMed

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., et al. (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14), 1345–1356. https://doi.org/10.1056/NEJMoa1709684.CrossRefPubMed

10.

Schadendorf, D., Larkin, J., Wolchok, J., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., et al. (2017). Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 82, 80–91. https://doi.org/10.1016/j.ejca.2017.05.031.CrossRefPubMedPubMedCentral

11.

European Medicines Agency. (2014). Revised framework for interaction between the European Medicines Agency and patients and consumers and their organisations. http://attwww.ema.europa.eu/docs/en_GB/document_library/Other/2009/12/WC500018013.pdf.

12.

Postmus, D., Richard, S., Bere, N., van Valkenhoef, G., Galinsky, J., Low, E., et al. (2018). Individual trade-offs between possible benefits and risks of cancer treatments: Results from a stated preference study with patients with multiple myeloma. The Oncologist, 23(1), 44–51. https://doi.org/10.1634/theoncologist.2017-0257.CrossRefPubMed

13.

Postmus, D., Mavris, M., Hillege, H. L., Salmonson, T., Ryll, B., Plate, A., et al. (2016). Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators. Clinical Pharmacology and Therapeutics, 99(5), 548–554. https://doi.org/10.1002/cpt.332.CrossRefPubMed

14.

U. S. Food and Drug Administration. (2017). Plan for issuance of patient-focused drug development guidance under 21st century cures act title III section 3002. https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm563618.pdf.

15.

Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G., et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573.CrossRefPubMed

16.

Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., et al. (2015). American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options. Journal of Clinical Oncology, 33(23), 2563–2577. https://doi.org/10.1200/JCO.2015.61.6706.CrossRefPubMedPubMedCentral

17.

Solem, C. T., Kwon, Y., Shah, R. M., Aly, A., & Botteman, M. F. (2018). Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology. Expert Review of Pharmacoeconomics Outcomes Research, 5, 1–9. https://doi.org/10.1080/14737167.2018.1434414.CrossRef

18.

Goldhirsch, A., Gelber, R. D., Simes, R. J., Glasziou, P., & Coates, A. S. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. Journal of Clinical Oncology, 7(1), 36–44. https://doi.org/10.1200/JCO.1989.7.1.36.CrossRefPubMed

19.

Revicki, D. A., Feeny, D., Hunt, T. L., & Cole, B. F. (2006). Analyzing oncology clinical trial data using the Q-TWiST method: Clinical importance and sources for health state preference data. Quality of Life Research, 15(3), 411–423. https://doi.org/10.1007/s11136-005-1579-7.CrossRefPubMed

20.

Chung, H. C., Bang, Y., Van Cutsem, E., Kang, Y., Hamamoto, Y., Moiseyenko, V., et al. (2010). (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin(T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. Journal of Clinical Oncology, 28, 4048.CrossRef

21.

Sherrill, B., Wang, J., Kotapati, S., & Chin, K. (2013). Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. British Journal of Cancer, 109(1), 8–13. https://doi.org/10.1038/bjc.2013.298.CrossRefPubMedPubMedCentral

22.

Kilbridge, K. L., Cole, B. F., Kirkwood, J. M., Haluska, F. G., Atkins, M. A., Ruckdeschel, J. C., et al. (2002). Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. Journal of Clinical Oncology, 20(5), 1311–1318. https://doi.org/10.1200/JCO.2002.20.5.1311.CrossRefPubMed

23.

Cole, B. F., Solal-Celigny, P., Gelber, R. D., Lepage, E., Gisselbrecht, C., Reyes, F., et al. (1998). Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making. Journal of Clinical Oncology, 16(7), 2339–2344. https://doi.org/10.1200/JCO.1998.16.7.2339.CrossRefPubMed

24.

Patil, S., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Negrier, S., Kim, S. T., et al. (2012). Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-alpha. British Journal of Cancer, 106(10), 1587–1590. https://doi.org/10.1038/bjc.2012.149.CrossRefPubMedPubMedCentral

25.

Sloan, J. A., Sargent, D. J., Lindman, J., Allmer, C., Vargas-Chanes, D., Creagan, E. T., et al. (2002). A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot. Quality of Life Research, 11(1), 37–45.CrossRefPubMed

26.

Zbrozek, A. S., Hudes, G., Levy, D., Strahs, A., Berkenblit, A., DeMarinis, R., et al. (2010). Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics, 28(7), 577–584. https://doi.org/10.2165/11535290-000000000-00000.CrossRefPubMed

27.

Zee, B., Cole, B., Li, T., Browman, G., James, K., Johnston, D., et al. (1998). Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. Journal of Clinical Oncology, 16(8), 2834–2839. https://doi.org/10.1200/JCO.1998.16.8.2834.CrossRefPubMed

28.

Lafuma, A., Dreno, B., Delaunay, M., Emery, C., Fagnani, F., Hieke, K., et al. (2001). Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. European Journal of Cancer, 37(3), 369–375.CrossRefPubMed

29.

Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E., & Borden, E. (1996). Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, 14(10), 2666–2673. https://doi.org/10.1200/JCO.1996.14.10.2666.CrossRefPubMed

30.

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1), 23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMed

31.

Gelber, R. D., Cole, B., Gelber, S., & Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: The Q-TWiST method. The American Statistician, 49, 161–169.

32.

Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.CrossRefPubMed

33.

Haanen, J., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., et al. (2017). Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(suppl_4), iv119–iv142. https://doi.org/10.1093/annonc/mdx225.CrossRefPubMed

34.

Gelber, R. D., & Goldhirsch, A. (1986). A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. Journal of Clinical Oncology, 4(12), 1772–1779. https://doi.org/10.1200/JCO.1986.4.12.1772.CrossRefPubMed

35.

Fenton, J. J., Duberstein, P. R., Kravitz, R. L., Xing, G., Tancredi, D. J., Fiscella, K., et al. (2018). Impact of prognostic discussions on the patient-physician relationship: Prospective cohort study. Journal of Clinical Oncology, 36, 225–230. https://doi.org/10.1200/JCO.2017.75.6288.CrossRefPubMedPubMedCentral

36.

Wolchok, J. D., Hoos, A., O’Day, S., Weber, J. S., Hamid, O., Lebbé, C., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15, 7412–7420.CrossRefPubMed

37.

Jessy, T. (2011). Immunity over inability: The spontaneous regression of cancer. Journal of Natural Science, Biology, and Medicine, 2(1), 43–49. https://doi.org/10.4103/0976-9668.82318.CrossRefPubMedPubMedCentral

38.

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., et al. (2017). iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, 18(3), e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8.CrossRefPubMed

Titel: Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
Auteurs: David F. McDermott
Ruchit Shah
Komal Gupte-Singh
Javier Sabater
Linlin Luo
Marc Botteman
Sumati Rao
Meredith M. Regan
Michael Atkins
Publicatiedatum: 06-09-2018
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 1/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-018-1984-3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 1/2019

Factor structure and measurement invariance of the Subjective Vitality Scale: evidence from Chinese adolescents in Hong Kong

The prognostic value of health-related quality of life in patients with Chagas heart disease

Normative values for the distress thermometer (DT) and the emotion thermometers (ET), derived from a German general population sample

Association between preoperative anaemia and blood transfusion with long-term functional and quality of life outcomes amongst patients undergoing primary total knee arthroplasty in Singapore: a single-centre retrospective study

Confirmatory factor analysis of the Minnesota living with heart failure questionnaire among patients following open heart surgery for valve dysfunction

Changes and determinants of health-related quality of life among people newly diagnosed with HIV in China: a 1-year follow-up study